New and emerging regulators of intestinal lipoprotein secretion

Atherosclerosis

Volumn 233, Issue 2, 2014, Pages 608-615

  Xiao, Changting ^a,b   Dash, Satya ^a,b   Morgantini, Cecilia ^a,b   Lewis, Gary F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Chylomicron; GLP 1; GLP 2; Intestine; Lipoprotein; Resveratrol

Indexed keywords

BILE ACID; CARBOHYDRATE; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 2; LIPOPROTEIN; RESVERATROL; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CARBOHYDRATE DIET; CHYLOMICRON; EXENDIN 4; FAT INTAKE; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INCRETIN; INSULIN; PEPTIDE; STILBENE DERIVATIVE; TRIACYLGLYCEROL; VENOM;

ATHEROSCLEROSIS; BILE ACID METABOLISM; CHOLESTEROL METABOLISM; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; INTESTINAL SECRETION; INTESTINE FLORA; LIPOPROTEIN SECRETION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARBOHYDRATE DIET; CLINICAL TRIAL (TOPIC); DRUG SCREENING; DYSLIPIDEMIAS; FAT INTAKE; METABOLISM; MICROBIOLOGY; MICROFLORA; PATHOPHYSIOLOGY; PHARMACOLOGY; PHYSIOLOGY; SECRETION (PROCESS); SECRETION RATE; SMALL INTESTINE;

ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEIN B-48; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CHOLESTEROL; CHYLOMICRONS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIETARY CARBOHYDRATES; DIETARY FATS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG EVALUATION, PRECLINICAL; DYSLIPIDEMIAS; FATTY ACIDS, NONESTERIFIED; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INCRETINS; INSULIN; INSULIN RESISTANCE; INTESTINE, SMALL; LIPOPROTEINS; MICROBIOTA; PEPTIDES; RECEPTORS, GLUCAGON; SECRETORY RATE; STILBENES; TRIGLYCERIDES; VENOMS;

EID: 84896281665     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.047     Document Type: Review

References (127)

1. Bornfeldt K.E., Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011, 14:575-585.
2. Ginsberg H.N. Insulin resistance and cardiovascular disease. JClin Invest 2000, 106:453-458.
3. Ginsberg H.N., Maccallum P.R. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. JCardiometab Syndr 2009, 4:113-119.
4. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
5. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
6. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-485.
7. Proctor S.D., Mamo J.C. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 2003, 23:1595-1600.
8. de Man F.H., Cabezas M.C., van Barlingen H.H., Erkelens D.W., de Bruin T.W. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 1996, 26:89-108.
9. Mero N., Malmstrom R., Steiner G., Taskinen M.R., Syvanne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000, 150:167-177.
10. Nordestgaard B.G., Tybjaerg-Hansen A. IDL, VLDL, chylomicrons and atherosclerosis. Eur J Epidemiol 1992, 8(Suppl.1):92-98.
11. Doi H., Kugiyama K., Ohgushi M., et al. Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation. Atherosclerosis 1998, 137:341-349.
12. Twickler T.B., Dallinga-Thie G.M., Cohn J.S., Chapman M.J. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004, 109:1918-1925.
13. Curtin A., Deegan P., Owens D., Collins P., Johnson A., Tomkin G.H. Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol 1996, 33:205-210.
14. Hogue J.C., Lamarche B., Tremblay A.J., Bergeron J., Gagne C., Couture P. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. JLipid Res 2007, 48:1336-1342.
15. Schaefer E.J., McNamara J.R., Shah P.K., et al. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002, 25:989-994.
16. Chan D.C., Wong A.T., Yamashita S., Watts G.F. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment. Atherosclerosis 2012, 221:484-489.
17. Lapice E., Cipriano P., Patti L., Romano G., Vaccaro O., Rivellese A.A. Fasting apolipoprotein B48 is associated with asymptomatic peripheral arterial disease in type 2 diabetic subjects: a case-control study. Atherosclerosis 2012, 223:504-506.
18. Masuda D., Sugimoto T., Tsujii K., et al. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Invest 2012, 42:992-999.
19. Masuda D., Sakai N., Sugimoto T., et al. Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia. JAtheroscler Thromb 2011, 18:1062-1070.
20. Nakatani K., Sugimoto T., Masuda D., et al. Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels. Atherosclerosis 2011, 218:226-232.
21. Alipour A., Valdivielso P., Elte J.W., et al. Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. Eur J Clin Invest 2012, 42:702-708.
22. Yuasa-Kawase M., Masuda D., Kitazume-Taneike R., et al. Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after antihyperlipidemic intervention. JAtheroscler Thromb 2012, 19:862-871.
23. Lewis G.F., Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005, 96:1221-1232.
24. Krauss R.M. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol 2010, 21:305-311.
25. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004, 27:1496-1504.
26. Adiels M., Matikainen N., Westerbacka J., et al. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 2012, 222:222-228.
27. Pang J., Chan D.C., Barrett P.H., Watts G.F. Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects. Curr Opin Lipidol 2012, 23:303-309.
28. Choi S.H., Ginsberg H.N. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab 2011, 22:353-363.
29. Adiels M., Olofsson S.O., Taskinen M.R., Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
30. Xiao C., Hsieh J., Adeli K., Lewis G.F. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am J Physiol Endocrinol Metab 2011, 301:E429-E446.
31. Adeli K., Lewis G.F. Intestinal lipoprotein overproduction in insulin-resistant states. Curr Opin Lipidol 2008, 19:221-228.
32. Lewis G.F., Uffelman K.D., Szeto L.W., Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 1993, 42:833-842.
33. Lewis G.F., Uffelman K.D., Szeto L.W., Weller B., Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. JClin Invest 1995, 95:158-166.
34. Pavlic M., Xiao C., Szeto L., Patterson B.W., Lewis G.F. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes 2010, 59:580-587.
35. Malmstrom R., Packard C.J., Caslake M., et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997, 40:454-462.
36. Nogueira J.P., Maraninchi M., Beliard S., et al. Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes. Arterioscler Thromb Vasc Biol 2012, 32:1039-1044.
37. Duez H., Lamarche B., Valero R., et al. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 2008, 117:2369-2376.
38. Xiao C., Pavlic M., Szeto L., Patterson B.W., Lewis G.F. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes 2011, 60:383-390.
39. Pan X., Hussain M.M. Gut triglyceride production. Biochim Biophys Acta 2012, 1821:727-735.
40. Iqbal J., Hussain M.M. Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009, 296:E1183-E1194.
41. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
42. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
43. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
44. Nielsen L.L., Young A.A., Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004, 117:77-88.
45. Gentilella R., Bianchi C., Rossi A., Rotella C.M. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab 2009, 11:544-556.
46. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
47. Mudaliar S., Henry R.R. Incretin therapies: effects beyond glycemic control. Eur J Intern Med 2009, 20(Suppl.2):S319-S328.
48. Xiao C., Dash S., Lewis G.F. Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system. Cardiovasc Hematol Agents Med Chem 2012, 10:289-294.
49. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
50. Matikainen N., Manttari S., Schweizer A., et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006, 49:2049-2057.
51. Matikainen N., Taskinen M.R. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes. Diabet Med 2013, 30:756-757.
52. Pratley R.E., Nauck M., Bailey T., et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456.
53. Schwartz S.L., Ratner R.E., Kim D.D., et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther 2008, 30:858-867.
54. Meier J.J., Gethmann A., Gotze O., et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49:452-458.
55. Schwartz E.A., Koska J., Mullin M.P., Syoufi I., Schwenke D.C., Reaven P.D. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010, 212:217-222.
56. Xiao C., Bandsma R.H., Dash S., Szeto L., Lewis G.F. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol 2012, 32:1513-1519.
57. Hsieh J., Longuet C., Baker C.L., et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010, 53:552-561.
58. Farr S., Naples M., Baker C., Adeli K. Glucagon-like peptide-1 reduces intestinal lipid availability and lipoprotein production via a gut-brain axis. Diabetes 2013, 62:A163.
59. Eliasson B., Moller-Goede D., Eeg-Olofsson K., et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 2012, 55:915-925.
60. Noda Y., Miyoshi T., Oe H., et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report. Cardiovasc Diabetol 2013, 12:8-15.
61. Xiao C, Dash S, Morgantini C, Patterson BW, Lewis GF. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans, Diabetes (in revision).
62. White W.B., Cannon C.P., Heller S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. NEngl J Med 2013, 369:1327-1335.
63. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. NEngl J Med 2013, 369:1317-1326.
64. Estall J.L., Drucker D.J. Glucagon-like peptide-2. Annu Rev Nutr 2006, 26:391-411.
65. Hsieh J., Longuet C., Maida A., et al. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology 2009, 137:997-1005.
66. Meier J.J., Nauck M.A., Pott A., et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006, 130:44-54.
67. Banasch M., Bulut K., Hagemann D., et al. Glucagon-like peptide 2 inhibits ghrelin secretion in humans. Regul Pept 2006, 137:173-178.
68. Masuda D., Hirano K., Oku H., et al. Chylomicron remnants are increased in the postprandial state in CD36 deficiency. JLipid Res 2009, 50:999-1011.
69. Dash S., Xiao C., Morgantini C., Szeto L., Patterson B.W., Lewis G.F. Glucagon-like peptide-2 acutely stimulates chylomicron release in healthy humans. Diabetes 2013, 62:A76-A77.
70. Yusta B., Huang L., Munroe D., et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000, 119:744-755.
71. Guan X., Karpen H.E., Stephens J., et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006, 130:150-164.
72. Bremholm L., Hornum M., Andersen U.B., Holst J.J. The effect of glucagon-like peptide-2 on arterial blood flow and cardiac parameters. Regul Pept 2010, 159:67-71.
73. Bremholm L., Hornum M., Andersen U.B., Hartmann B., Holst J.J., Jeppesen P.B. The effect of Glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept 2011, 168:32-38.
74. Hein G.J., Baker C., Hsieh J., Farr S., Adeli K. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes 2013, 62:373-381.
75. Baur J.A., Ungvari Z., Minor R.K., Le Couteur D.G., de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan?. Nat Rev Drug Discov 2012, 11:443-461.
76. Crandall J.P., Barzilai N. Exploring the promise of resveratrol: where do we go from here?. Diabetes 2013, 62:1022-1023.
77. Timmers S., Konings E., Bilet L., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011, 14:612-622.
78. Crandall J.P., Oram V., Trandafirescu G., et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. JGerontol A Biol Sci Med Sci 2012, 67:1307-1312.
79. Brasnyo P., Molnar G.A., Mohas M., et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011, 106:383-389.
80. Poulsen M.M., Vestergaard P.F., Clasen B.F., et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62:1186-1195.
81. Yoshino J., Conte C., Fontana L., et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 2012, 16:658-664.
82. Dash S., Xiao C., Morgantini C., Szeto L., Lewis G.F. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler Thromb Vasc Biol 2013, 33:2895-2901.
83. Dao T.M., Waget A., Klopp P., et al. Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One 2011, 6:e20700.
84. Cani P.D., Possemiers S., Van de Wiele T., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
85. Parks E.J., Hellerstein M.K. Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 2000, 71:412-433.
86. Bray G.A. Fructose and risk of cardiometabolic disease. Curr Atheroscler Rep 2012, 14:570-578.
87. Havel P.J. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev 2005, 63:133-157.
88. Stanhope K.L., Havel P.J. Fructose consumption: recent results and their potential implications. Ann N Y Acad Sci 2010, 1190:15-24.
89. Stanhope K.L., Bremer A.A., Medici V., et al. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. JClin Endocrinol Metab 2011, 96:E1596-E1605.
90. Parks E.J. Effect of dietary carbohydrate on triglyceride metabolism in humans. JNutr 2001, 131:2772S-2774S.
91. Chong M.F., Fielding B.A., Frayn K.N. Mechanisms for the acute effect of fructose on postprandial lipemia. Am J Clin Nutr 2007, 85:1511-1520.
92. Grant K.I., Marais M.P., Dhansay M.A. Sucrose in a lipid-rich meal amplifies the postprandial excursion of serum and lipoprotein triglyceride and cholesterol concentrations by decreasing triglyceride clearance. Am J Clin Nutr 1994, 59:853-860.
93. Parks E.J., Skokan L.E., Timlin M.T., Dingfelder C.S. Dietary sugars stimulate fatty acid synthesis in adults. JNutr 2008, 138:1039-1046.
94. Stanhope K.L., Griffen S.C., Bair B.R., Swarbrick M.M., Keim N.L., Havel P.J. Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. Am J Clin Nutr 2008, 87:1194-1203.
95. Jeppesen J., Chen Y.I., Zhou M.Y., Schaaf P., Coulston A., Reaven G.M. Postprandial triglyceride and retinyl ester responses to oral fat: effects of fructose. Am J Clin Nutr 1995, 61:787-791.
96. Abraha A., Humphreys S.M., Clark M.L., Matthews D.R., Frayn K.N. Acute effect of fructose on postprandial lipaemia in diabetic and non-diabetic subjects. Br J Nutr 1998, 80:169-175.
97. Teff K.L., Elliott S.S., Tschop M., et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. JClin Endocrinol Metab 2004, 89:2963-2972.
98. Cohen J.C., Schall R. Reassessing the effects of simple carbohydrates on the serum triglyceride responses to fat meals. Am J Clin Nutr 1988, 48:1031-1034.
99. Cohen J.C., Berger G.M. Effects of glucose ingestion on postprandial lipemia and triglyceride clearance in humans. JLipid Res 1990, 31:597-602.
100. Robertson M.D., Parkes M., Warren B.F., et al. Mobilisation of enterocyte fat stores by oral glucose in humans. Gut 2003, 52:834-839.
101. Xiao C., Dash S., Morgantini C., Lewis G.F. Novel role of enteral monosaccharides in intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol 2013, 33:1056-1062.
102. D'Souza V.M., Shertzer H.G., Menon A.G., Pauletti G.M. High glucose concentration in isotonic media alters caco-2 cell permeability. AAPS PharmSci 2003, 5:E24.
103. Komissarchik I., Snigirevskaia E.S., Brudnaia M.S., Gromova L.V., Gruzdkov A.A., Ugolev A.M. [An analysis of the structural characteristics of the tight junction of the enterocytes of the rat small intestine during nutrient absorption (immunoelectron microscopic research)]. Fiziol Zh Im I M Sechenova 1993, 79:57-64.
104. Pauquai T., Bouchoux J., Chateau D., et al. Adaptation of enterocytic Caco-2 cells to glucose modulates triacylglycerol-rich lipoprotein secretion through triacylglycerol targeting into the endoplasmic reticulum lumen. Biochem J 2006, 395:393-403.
105. Iizuka K. Recent progress on the role of ChREBP in glucose and lipid metabolism. Endocr J 2013, 60:543-555.
106. Tremblay A.J., Lamarche B., Guay V., Charest A., Lemelin V., Couture P. Short-term, high-fat diet increases the expression of key intestinal genes involved in lipoprotein metabolism in healthy men. Am J Clin Nutr 2013, 98:32-41.
107. Levy E., Spahis S., Ziv E., et al. Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids. Diabetologia 2006, 49:1937-1945.
108. Grenier E., Mailhort G., Dion D., et al. Role of the apical and basolateral domains of the enterocyte in the regulation of cholesterol transport by a high glucose concentration. Biochem Cell Biol 2013, 91:476-486.
109. Naples M., Baker C., Lino M., Iqbal J., Hussain M.M., Adeli K. Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. Am J Physiol Gastrointest Liver Physiol 2012, 302:G1043-G1052.
110. Yagi S., Akaike M., Aihara K., Iwase T., et al. Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. JAtheroscler Thromb 2010, 17:173-180.
111. Park H., Shima T., Yamaguchi K., et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. JGastroenterol 2011, 46:101-107.
112. Chan D.C., Watts G.F., Gan S.K., Ooi E.M., Barrett P.H. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010, 33:1134-1139.
113. Bozzetto L., Annuzzi G., Corte G.D., et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 2011, 217:142-148.
114. Kikuchi K., Nezu U., Inazumi K., et al. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. JAtheroscler Thromb 2012, 19:1093-1101.
115. Tremblay A.J., Lamarche B., Hogue J.C., Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. JLipid Res 2009, 50:1463-1471.
116. During A., Dawson H.D., Harrison E.H. Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. JNutr 2005, 135:2305-2312.
117. Parker H.E., Wallis K., le Roux C.W., Wong K.Y., Reimann F., Gribble F.M. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol 2012, 165:414-423.
118. Beysen C., Murphy E.J., Deines K., et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 2012, 55:432-442.
119. Le M.C., Berger J.M., Lespine A., et al. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler Thromb Vasc Biol 2013, 33:1484-1493.
120. Tietge U.J., Groen A.K. Role the TICE?: advancing the concept of transintestinal cholesterol excretion. Arterioscler Thromb Vasc Biol 2013, 33:1452-1453.
121. Karlsson F., Tremaroli V., Nielsen J., Backhed F. Assessing the human gut microbiota in metabolic diseases. Diabetes 2013, 62:3341-3349.
122. Tremaroli V., Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489:242-249.
123. Backhed F. Meat-metabolizing bacteria in atherosclerosis. Nat Med 2013, 19:533-534.
124. Caesar R., Fak F., Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. JIntern Med 2010, 268:320-328.
125. Howitt M.R., Garrett W.S. Acomplex microworld in the gut: gut microbiota and cardiovascular disease connectivity. Nat Med 2012, 18:1188-1189.
126. Loscalzo J. Gut microbiota, the genome, and diet in atherogenesis. NEngl J Med 2013, 368:1647-1649.
127. Sayin S.I., Wahlstrom A., Felin J., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013, 17:225-235.